01—Abstract
Summary
Summary of the 8-K filed April 28, 2026. Cited figures are marked; the original filing is the authoritative source.
On April 28, 2026, Gilead Sciences completed its acquisition of Arcellx, Inc. (Nasdaq: ACLX) through a tender offer followed by a Section 251(h) merger.
Shareholders receive $115.00a per share in cash plus one non-transferable contingent value right (CVR) worth up to $5.00 per share. Gilead describes the transaction as a total implied equity value of about $7.8 billion, and it used roughly $7.1 billion of cash to fund the Offer and Merger, including option, RSU and other payments. The tender offer expired April 27, 2026, with about 38.8 million shares tendered, which together with shares Gilead already owned represented approximately 77.2% of outstanding shares.
This cleared the majority-of-shares threshold, and Arcellx is now a wholly owned subsidiary and will be delisted from Nasdaq. The strategic rationale centers on full control of anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T-cell therapy for multiple myeloma that Kite had been collaborating on with Arcellx. Gilead says the deal eliminates future profit-share, milestone and royalty obligations, allowing it to consolidate development and decision-making and bring the program to patients.
Management frames the next phase as execution on the regulatory and commercial launch, with anito-cel carrying Fast Track, Orphan Drug and RMAT designations from the FDA. For investors, the key financial effects are on earnings rather than near-term cash flow. Because the deal is accounted for as an asset acquisition, the acquired in-process R&D expense is expected to reduce Gilead's 2026 GAAP and non-GAAP diluted EPS by approximately $5.57 to $5.67b.
Excluding that charge, Gilead expects modest dilution in 2026 and 2027 and accretion from 2028 onward, contingent on FDA approval of anito-cel. The $5.00c CVR adds a further contingent liability tied to cumulative anito-cel sales exceeding $6.0 billion through December 31, 2029, with any payment due March 31, 2030.
02—Key points
Key Highlights
- Acquisition closed April 28, 2026: $115.00 per share in cash plus one CVR of $5.00 per share, for a total implied equity value of about $7.8 billion.
- Tender offer met its minimum condition: about 38.8 million shares tendered, representing approximately 77.2% of outstanding shares together with shares already owned by Gilead.
- Cash outlay of approximately $7.1 billion, including option, RSU and other payments made under the merger agreement.
- Accounting as an asset acquisition drives a one-time 2026 EPS reduction of approximately $5.57 to $5.67 (GAAP and non-GAAP) from acquired in-process R&D expense.
- Excluding the IPR&D charge, Gilead expects modest EPS dilution in 2026 and 2027 and accretion in 2028 and beyond, subject to FDA approval of anito-cel.
- Gilead gains full control of anito-cel and eliminates future profit-share, milestone and royalty obligations to Arcellx.
- CVR payout of $5.00 per share is contingent on cumulative anito-cel sales of at least $6.0 billion through December 31, 2029, payable March 31, 2030.
03—Questions
Frequently Asked Questions
What did Arcellx shareholders receive in the transaction?
Each share was converted into the right to receive $115.00 in cash, without interest and subject to withholding tax, plus one non-transferable CVR. The CVR entitles the holder to a $5.00 cash payment if cumulative worldwide anito-cel sales reach at least $6.0 billion on or before December 31, 2029, payable March 31, 2030.
Why does the transaction reduce Gilead's 2026 EPS so significantly?
Gilead is accounting for the deal as an asset acquisition, so the acquired in-process R&D is expensed immediately rather than capitalized. That charge is expected to reduce 2026 GAAP and non-GAAP diluted EPS by about $5.57 to $5.67. Gilead says the underlying business effect is modestly dilutive in 2026 and 2027 and accretive from 2028, excluding this charge.
Why was the total value of about $7.8 billion different from the $7.1 billion of funds used?
The filing does not fully reconcile the two figures. The $7.8 billion is an implied equity value that reflects the cash price and the CVR, while the $7.1 billion is the cash Gilead actually used to consummate the Offer and Merger. The CVR is contingent and its value is not paid at closing, so the gap likely reflects that contingent component and other accounting treatment, which investors should confirm in Gilead's upcoming periodic reports.
What are the main risks to the anticipated benefits?
Key risks include the timing and outcome of FDA approval for anito-cel, which is required for the expected accretion from 2028, and the possibility that the CVR milestone of $6.0 billion in cumulative sales through 2029 is not achieved, in which case no CVR payment is made. Integration risk, competitive pricing pressure, and transaction-related liabilities are also cited in the forward-looking statements.
Will Arcellx still trade publicly?
No. Following completion of the merger, Arcellx became a wholly owned subsidiary of Gilead, and its common stock will be delisted from the Nasdaq Global Select Market. Former shareholders no longer hold equity in Arcellx and instead receive the cash consideration and CVR described above.
04—Continue